Adverse events222

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 222

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Arm A: Vixarelimab 720 mg Q2W	0	27	0
other	Anaemia	Blood and lymphatic system disorders	Arm B: Vixarelimab 720 mg Q4W	0	26	0
other	Anaemia	Blood and lymphatic system disorders	Arm C: Placebo	0	26	0
other	Anaemia	Blood and lymphatic system disorders	Arm A: Vixarelimab 720 mg Q2W to Vixarelimab 720 mg Q2W	1	15	1
other	Anaemia	Blood and lymphatic system disorders	Arm B: Vixarelimab 720 mg Q4W to Vixarelimab 720 mg Q4W	0	10	0
other	Anaemia	Blood and lymphatic system disorders	Arm C: Placebo to Vixarelimab 720 mg Q2W	1	17	1
other	Atrioventricular block first degree	Cardiac disorders	Arm A: Vixarelimab 720 mg Q2W	0	27	0
other	Atrioventricular block first degree	Cardiac disorders	Arm B: Vixarelimab 720 mg Q4W	0	26	0
other	Atrioventricular block first degree	Cardiac disorders	Arm C: Placebo	0	26	0
other	Atrioventricular block first degree	Cardiac disorders	Arm A: Vixarelimab 720 mg Q2W to Vixarelimab 720 mg Q2W	0	15	0
other	Atrioventricular block first degree	Cardiac disorders	Arm B: Vixarelimab 720 mg Q4W to Vixarelimab 720 mg Q4W	0	10	0
other	Atrioventricular block first degree	Cardiac disorders	Arm C: Placebo to Vixarelimab 720 mg Q2W	1	17	1
other	Conjunctival haemorrhage	Eye disorders	Arm A: Vixarelimab 720 mg Q2W	0	27	0
other	Conjunctival haemorrhage	Eye disorders	Arm B: Vixarelimab 720 mg Q4W	0	26	0
other	Conjunctival haemorrhage	Eye disorders	Arm C: Placebo	0	26	0
other	Conjunctival haemorrhage	Eye disorders	Arm A: Vixarelimab 720 mg Q2W to Vixarelimab 720 mg Q2W	1	15	1
other	Conjunctival haemorrhage	Eye disorders	Arm B: Vixarelimab 720 mg Q4W to Vixarelimab 720 mg Q4W	0	10	0
other	Conjunctival haemorrhage	Eye disorders	Arm C: Placebo to Vixarelimab 720 mg Q2W	0	17	0
other	Colitis ulcerative	Gastrointestinal disorders	Arm A: Vixarelimab 720 mg Q2W	2	27	2
other	Colitis ulcerative	Gastrointestinal disorders	Arm B: Vixarelimab 720 mg Q4W	3	26	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06137183/events

API reference For AI assistants

Adverse events222

Sources 3

Read this list from software.